US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2024
0mins
Source: Reuters
Supreme Court Decision: The U.S. Supreme Court declined to hear Norwich Pharmaceuticals' appeal against a lower court ruling that blocked its attempt to sell a generic version of Bausch Health's Xifaxan, citing patent infringement concerns related to treating hepatic encephalopathy.
Financial Impact: Bausch Health earned over $1.8 billion from Xifaxan sales in 2023, while Norwich argued that the delay in introducing generic alternatives would lead to higher costs for patients and the healthcare system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
